Skip to main content

Table 1 Summary of tumor response and survival outcomes according to RECIST 1.1 criteria

From: Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

Outcomes

Combination group (n = 32), n (%)

Chemotherapy group (n = 64), n (%)

P value

Best tumor response

 Complete response

0 (0%)

0 (0%)

 

 Partial response

9 (28.1)

14 (21.9)

0.499

 Stable disease

20 (62.5)

36 (56.3)

0.558

 Progressive disease

3 (9.4)

14 (21.9)

0.163

Objective response rate

9 (28.1)

14 (21.9)

0.499

Disease control rate

29 (90.6)

50 (78.1)

0.163

Median OS (mo)*

22.3 ± 2.9 (16.6–28.0)

18.6 ± 2.7 (13.3–23.9)

0.031

Median PFS (mo)*

12.0 ± 3.1 (5.8–18.1)

10.5 ± 2.2 (6.3–14.7)

0.043

  1. RECIST Response Evaluation Criteria in Solid Tumors, OS overall survival, PFS progression-free survival
  2. *Data in parentheses are the 95% confidence interval